Ottawa Hospital

Running trials

• Not yet recruiting

  A Phase 1 Clinical Trial of Adjuvanted Protein-based HCV Vaccine Candidates (HCV Vaccine Trial)

  NCT07237282· Phase 1· University of Alberta· Source

• Not yet recruiting

  SPIRO-First: A Pragmatic Primary Care-Embedded Pilot Trial of Renin-Guided First-Line Antihypertensive Therapy

  NCT07687160· Phase 4· Ottawa Hospital Research Institute· Source

• Not yet recruiting

  Mycophenolate After Stem Cell Transplant for Systemic Sclerosis

  NCT07734012· Phase 2· Ottawa Hospital Research Institute· Source

• Not yet recruiting

  Cardiac CT Angiography in Acute Stroke Imaging (SCOPE-CT)

  NCT07896889· Ottawa Hospital Research Institute· Source

• Not yet recruiting

  Phase II Study of CAmizestrant in Resectable Endometrial Adenocarcinoma

  NCT07840443· Phase 2· University Health Network, Toronto· Source

• Recruiting

  DAREON®-NEC-1: A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer (epNEC) to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard Chemotherapy

  NCT07544654· Phase 3· Boehringer Ingelheim· Source

• Recruiting

  Psilocybin-Assisted Therapy for Treatment-Resistant Depression in Bipolar II Disorder

  NCT06943573· Phase 2· Lakshmi N Yatham· Source

• Recruiting

  The PARTUM Trial: Postpartum Aspirin to Reduce Thromboembolism Undue Morbidity

  NCT06494878· Phase 3· University of Calgary· Source

• Recruiting

  Safety of Perioperative Anticoagulation Management in People With Active Cancer Undergoing Cancer-Related Surgery or Procedures (ACE-HIGH Study)

  NCT07372716· Ottawa Hospital Research Institute· Source

• Recruiting

  Study of KITE-363 in Participants With Autoimmune Neurologic Diseases That Did Not Respond to Usual Treatment

  NCT07304154· Phase 1· Kite, A Gilead Company· Source

• Recruiting

  Advanced Brain Imaging-TKA (fMRI-TKA)

  NCT07464080· Ottawa Hospital Research Institute· Source

• Recruiting

  A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)

  NCT07361497· Phase 3· Bristol-Myers Squibb· Source

• Recruiting

  Canadian Consortium on Airway Mucus Occlusions in Asthma, COPD and Chronic Cough

  NCT06858748· McMaster University· Source

• Recruiting

  First-in-Human Study of ALN-SNCA in Adult Participants With Early Parkinson's Disease (PD)

  NCT07216066· Phase 1· Regeneron Pharmaceuticals· Source

• Recruiting

  Safe Effective Therapy With Low-Dose Glucocorticoid in ANCA-Associated Vasculitis (SAFE-LOW)

  NCT06983821· Phase 3· Ottawa Hospital Research Institute· Source

• Recruiting

  A Study in Participants With Active Systemic Lupus Erythematosus With Inadequate Response to Glucocorticoids and ≥2 Immunosuppressants

  NCT07175285· Bristol-Myers Squibb· Source

• Recruiting

  A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue

  NCT06989437· Phase 2/3· Pfizer· Source

• Recruiting

  A First in Human Study to Assess the Safety, Tolerability, and Pharmacokinetics of EDK060 in Adults With CMT1A.

  NCT07140614· Phase 1· Novartis Pharmaceuticals· Source

• Recruiting

  A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)

  NCT06926868· Phase 2/3· Bristol-Myers Squibb· Source

• Not yet recruiting

  Do Blood Tests Help to Decide Which Patients With Flares of Chronic Obstructive Pulmonary Disease (COPD) Need Antibiotics and Steroids?

  NCT06929767· Phase 4· Ottawa Hospital Research Institute· Source

• Recruiting

  A Research Study to See How Well Weekly Insulin Icodec Maintains Blood Sugar Levels Compared to Daily Basal Insulins in Adults With Type 2 Diabetes

  NCT07112339· Phase 4· Novo Nordisk A/S· Source

• Recruiting

  DIALysis With EXpanded Solute Removal

  NCT06660277· London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's· Source

• Recruiting

  A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer

  NCT07005102· Phase 2/3· AbbVie· Source

• Recruiting

  Personalized Hypoglycemia Outpatient Treatment - a Feasibility Study

  NCT07094529· Ottawa Hospital Research Institute· Source

• Recruiting

  Feasibility Trial for a Right Ventricular Failure Platform Trial

  NCT06570473· Phase 2· University of Alberta· Source

• Enrolling by invitation

  A Study of KITE-363 in Participants With Refractory Autoimmune Diseases

  NCT07038447· Phase 1· Kite, A Gilead Company· Source

• Recruiting

  Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study

  NCT06937086· Phase 3· Eli Lilly and Company· Source

• Recruiting

  Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight

  NCT06937099· Phase 3· Eli Lilly and Company· Source

• Recruiting

  Left Atrial Imaging Prior to Cardioversion: Leveraging Computed Tomography to Rule Out Thrombus in The Emergency Department (LA CLOTTED)

  NCT07002450· Ottawa Heart Institute Research Corporation· Source

• Recruiting

  A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)

  NCT06943872· Phase 3· BeOne Medicines· Source

• Active, not recruiting

  A Study to Evaluate Efficacy, Safety and Tolerability of Hydroxychloroquine in Subjects With Parkinson's Disease

  NCT06816810· Phase 2· Ottawa Hospital Research Institute· Source

• Recruiting

  A Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368 in Participants With Multiple Sclerosis Spasticity

  NCT06782490· Phase 2· Celgene· Source

• Recruiting

  Study of Diosmin for the Treatment of Digital Ulcers in Systemic Sclerosis

  NCT06256575· Primus Pharmaceuticals· Source

• Recruiting

  The Dragon PLC Trial (DRAGON-PLC)

  NCT06914648· Maastricht University· Source

• Recruiting

  Perioperative Anticoagulant Use for Surgery Evaluation -2 (PAUSE-2) Study Patients Receiving a Direct Oral Anticoagulant (DOACs-Dabigatran, Rivaroxaban, Apixaban or Edoxaban) and Needing Elective High-Bleed-Risk Surgery or an Invasive Procedure

  NCT06957366· McMaster University· Source

• Recruiting

  Outpatient and Intermittent Dosing of Elranatamab in Relapsed/Refractory Multiple Myeloma

  NCT06421675· Phase 2· Ontario Clinical Oncology Group (OCOG)· Source

• Recruiting

  A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors

  NCT06618287· Phase 1/2· Bristol-Myers Squibb· Source

• Recruiting

  CLIC-2201 for the Treatment of Relapsed/Refractory B Cell Malignancies

  NCT06208735· Phase 1· British Columbia Cancer Agency· Source

• Active, not recruiting

  A Trial of Amlenetug (Lu AF82422) in Participants With Multiple System Atrophy (MSA)

  NCT06706622· Phase 3· H. Lundbeck A/S· Source

• Active, not recruiting

  Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML

  NCT06578247· Phase 3· Daiichi Sankyo· Source

• Active, not recruiting

  SpaceIT Hydrogel System for Perirectal Spacing

  NCT06451614· Boston Scientific Corporation· Source

• Recruiting

  A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer

  NCT06662786· Phase 3· Janssen Research & Development, LLC· Source

• Active, not recruiting

  A Study Observing Everyday Effectiveness and Safety of the Drug Elafibranor in Participants With Primary Biliary Cholangitis Who Are Receiving Ongoing Treatment

  NCT06447168· Ipsen· Source

• Recruiting

  Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma

  NCT06561048· Phase 3· Corvus Pharmaceuticals, Inc.· Source

• Active, not recruiting

  MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors

  NCT06586515· Phase 1· Eli Lilly and Company· Source

• Active, not recruiting

  EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin)

  NCT06531824· Phase 3· Boehringer Ingelheim· Source

• Active, not recruiting

  A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma

  NCT06413498· Phase 3· Kite, A Gilead Company· Source

• Active, not recruiting

  A Study Comparing Venetoclax and Azacitidine Plus Cusatuzumab to Venetoclax and Azacitidine in Newly Diagnosed AML Ineligible for Intensive Therapy

  NCT06384261· Phase 2· OncoVerity, Inc.· Source

• Active, not recruiting

  A Study of Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Plus Enfortumab Vedotin (EV) With and Without Pembrolizumab in Advanced Urothelial Carcinoma (MK-3475-04C/KEYMAKER-U04)

  NCT06483334· Phase 1/2· Merck Sharp & Dohme LLC· Source

• Recruiting

  Early Diagnosis and Treatment of Undiagnosed Asthma or COPD: THE UCAP 2 TRIAL

  NCT06392776· Ottawa Hospital Research Institute· Source

Showing 50 of 144.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Atrial fibrillation8 recruiting
• Lung cancer7 recruiting
• Chronic lymphocytic leukaemia5 recruiting
• Osteoarthritis5 recruiting
• Asthma4 recruiting
• Stroke4 recruiting
• Childhood cancers3 recruiting
• Colorectal cancer3 recruiting
• COPD3 recruiting
• Liver and biliary tract cancer3 recruiting
• Sarcoma3 recruiting
• Systemic sclerosis (scleroderma)3 recruiting
• Triple-negative breast cancer3 recruiting
• Type 2 diabetes3 recruiting
• Acute lymphoblastic leukaemia2 recruiting
• Gastric and oesophageal cancer2 recruiting
• High blood pressure2 recruiting
• Huntington's disease2 recruiting
• Lupus (SLE)2 recruiting
• Mantle cell lymphoma2 recruiting
• Multiple sclerosis2 recruiting
• Obesity2 recruiting
• Pancreatic cancer2 recruiting
• Parkinson disease2 recruiting
• Prostate cancer2 recruiting
• ANCA-associated vasculitis1 recruiting
• Bipolar disorder1 recruiting
• Bladder cancer1 recruiting
• Charcot-Marie-Tooth disease1 recruiting
• Chronic kidney disease1 recruiting
• CIDP (chronic inflammatory demyelinating polyneuropathy)1 recruiting
• Crohn's disease1 recruiting
• Depression1 recruiting
• Dermatomyositis and polymyositis (myositis)1 recruiting
• Diffuse large B-cell lymphoma1 recruiting
• Endometrial cancer1 recruiting
• Heart failure1 recruiting
• Hepatitis C1 recruiting
• Liver cirrhosis1 recruiting
• Melanoma1 recruiting
• Metastatic breast cancer1 recruiting
• Multiple myeloma1 recruiting
• Myasthenia gravis1 recruiting
• Neuroendocrine tumours1 recruiting
• Peripheral artery disease1 recruiting
• Primary biliary cholangitis1 recruiting
• Pulmonary arterial hypertension1 recruiting
• Type 1 diabetes1 recruiting
• Ulcerative colitis1 recruiting

Closed trials

• Terminated

  Adjunctive Intravenous Ascorbic Acid for Advanced Non-Small Cell Lung Cancer

  NCT05849129· Phase 2· The Canadian College of Naturopathic Medicine· Source

• Withdrawn

  The UCAP 2 Pilot Study

  NCT06014840· Ottawa Hospital Research Institute· Source

• Completed

  RECLAIM: Recovering From COVID-19 Lingering Symptoms Adaptive Integrative Medicine

  NCT05513560· Phase 2/3· University Health Network, Toronto· Source

• Completed

  Intra-Operative Adductor Canal Blocks

  NCT05601427· Ottawa Hospital Research Institute· Source

• Completed

  Can Pre-operative Anemia be Timely Identified and Optimized in Patients Awaiting Primary Arthroplasty Surgery? A Randomized Clinical Trial

  NCT05648942· Ottawa Hospital Research Institute· Source

• Completed

  Study of the Efficacy and Safety of Ponsegromab in Patients With Cancer, Cachexia and Elevated GDF-15

  NCT05546476· Phase 2· Pfizer· Source

• Completed

  An Efficacy, Safety, Tolerability, Immunogenicity, and Lot-Consistency Clinical Trial of a 6-Valent OspA-Based Lyme Disease Vaccine (VLA15)

  NCT05477524· Phase 3· Pfizer· Source

• Completed

  Brightline-1: A Study to Compare Brigimadlin (BI 907828) With Doxorubicin in People With a Type of Cancer Called Dedifferentiated Liposarcoma

  NCT05218499· Phase 2/3· Boehringer Ingelheim· Source

• Completed

  A Trial to Evaluate the Effects of Bifidobacterium Longum NCC3001 on Intestinal and Psychological Symptoms in Subjects With Irritable Bowel Syndrome

  NCT05054309· Société des Produits Nestlé (SPN)· Source

• Completed

  A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (MK-4280A-007)

  NCT05064059· Phase 3· Merck Sharp & Dohme LLC· Source

• Terminated

  MagnetisMM-4: Umbrella Study of Elranatamab (PF-06863135) in Combination With Anti-Cancer Treatments in Multiple Myeloma

  NCT05090566· Phase 2· Pfizer· Source

• Terminated

  A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age

  NCT05085366· Phase 3· ModernaTX, Inc.· Source

• Completed

  Study of WVE-003 in Patients With Huntington's Disease

  NCT05032196· Phase 1/2· Wave Life Sciences USA, Inc.· Source

• Completed

  Study to Assess the Efficacy and Safety of MT-3921 in Subjects With Acute Traumatic Cervical Spinal Cord Injury

  NCT04683848· Phase 2· Tanabe Pharma America, Inc.· Source

• Completed

  RAFF4 Trial: Vernakalant vs. Procainamide for Acute Atrial Fibrillation in the Emergency Department

  NCT04485195· Phase 4· Ottawa Hospital Research Institute· Source

• Completed

  An Observational Study to Evaluate the Clinical Utility of the Oncomine Precision Assay Within the Exactis Network

  NCT04564079· Exactis Innovation· Source

• Completed

  Assessing Feasibility of Thromboprophylaxis With Apixaban in JAK2-positive Myeloproliferative Neoplasm Patients

  NCT04243122· Phase 2· Ottawa Hospital Research Institute· Source

• Withdrawn

  Unicompartmental Knee Arthroplasty (UKA) Versus Total Knee Arthroplasty (TKA) of Medial Osteoarthritis

  NCT03457051· Ottawa Hospital Research Institute· Source

• Terminated

  HepTcell Immunotherapy in Patients With Inactive Chronic Hepatitis B (CHB)

  NCT04684914· Phase 2· Altimmune, Inc.· Source

• Completed

  A Trial of Enzastaurin Plus Temozolomide During and Following Radiation Therapy in Patients With Newly Diagnosed Glioblastoma With or Without the Novel Genomic Biomarker, DGM1

  NCT03776071· Phase 3· Denovo Biopharma LLC· Source

• Completed

  A Study of Pevonedistat and Venetoclax Combined With Azacitidine to Treat Acute Myeloid Leukemia (AML) in Adults Unable to Receive Intensive Chemotherapy

  NCT04266795· Phase 2· Takeda· Source

• Completed

  A Research Study to Compare a Medicine Called Semaglutide Against Placebo in People With Peripheral Arterial Disease and Type 2 Diabetes

  NCT04560998· Phase 3· Novo Nordisk A/S· Source

• Completed

  Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Who Are Receiving Chemotherapy and Radiation Therapy (MK-3475-975/KEYNOTE-975)

  NCT04210115· Phase 3· Merck Sharp & Dohme LLC· Source

• Completed

  A Study of Mirvetuximab Soravtansine vs. Investigator's Choice (IC) of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha (FRα) Expression

  NCT04209855· Phase 3· AbbVie· Source

• Completed

  Evaluation of Lasofoxifene Versus Fulvestrant in Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation

  NCT03781063· Phase 2· Sermonix Pharmaceuticals Inc.· Source

• Completed

  I-131-1095 Radioligand Plus Enzalutamide vs Enzalutamide for mCRPC That Progressed During Abiraterone (ARROW).

  NCT03939689· Phase 2· Progenics Pharmaceuticals, Inc.· Source

• Completed

  Evaluation of Efficacy and Safety of Neoadjuvant Treatment With Pamrevlumab in Combination With Chemotherapy (Either Gemcitabine Plus Nab-paclitaxel or FOLFIRINOX) in Participants With Locally Advanced, Unresectable Pancreatic Cancer

  NCT03941093· Phase 3· Kyntra Bio· Source

• Completed

  A Study of Biomarker-Directed, Pembrolizumab (MK-3475) Based Combination Therapy for Advanced Non-Small Cell Lung Cancer (MK-3475-495/KEYNOTE-495)

  NCT03516981· Phase 2· Merck Sharp & Dohme LLC· Source

• Completed

  PSMA-PET Registry for Recurrent Prostate Cancer

  NCT03718260· London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's· Source

• Completed

  This is an Extension Study of the Roche P-trials to Investigate Safety and Effectiveness of Ocrelizumab in Participants With Multiple Sclerosis (MS)

  NCT03599245· Phase 3· Hoffmann-La Roche· Source

• Terminated

  WAVe Study - Weight Adjusted Dalteparin for Patients Over 90 kg With Acute Cancer Associated Venous Thromboembolism

  NCT03297359· Phase 2· Ottawa Hospital Research Institute· Source

• Completed

  Study of Effectiveness of Axicabtagene Ciloleucel Compared to Standard of Care Therapy in Patients With Relapsed/Refractory Diffuse Large B Cell Lymphoma

  NCT03391466· Phase 3· Kite, A Gilead Company· Source

• Completed

  Does Cefoxitin or Piperacillin-Tazobactam Prevent Postoperative Surgical Site Infections After Pancreatoduodenectomy?

  NCT03269994· Phase 3· Memorial Sloan Kettering Cancer Center· Source

• Completed

  A Study Comparing the Efficacy and Safety of Polatuzumab Vedotin With Rituximab-Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Diffuse Large B-Cell Lymphoma

  NCT03274492· Phase 3· Hoffmann-La Roche· Source

• Completed

  A Study Comparing Obinutuzumab and BGB-3111 Versus Obinutuzumab Alone in Treating R/R Follicular Lymphoma

  NCT03332017· Phase 2· BeiGene· Source

• Completed

  A Clinical Study to Evaluate the Safety and Efficacy of Elagolix in Participants With Moderate to Severe Endometriosis-Associated Pain

  NCT03213457· Phase 3· AbbVie· Source

• Completed

  Long-term Extension to Study AC-058B301 to Investigate Safety, Tolerability and Disease Control of Ponesimod 20 mg in Patients With Relapsing Multiple Sclerosis

  NCT03232073· Phase 3· Actelion· Source

• Completed

  Folic Acid Clinical Trial: Follow up of Children (FACT 4 Child)

  NCT03269110· Ottawa Hospital Research Institute· Source

• Completed

  Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (MCL)

  NCT03112174· Phase 3· Pharmacyclics LLC.· Source

• Completed

  A Study of Rucaparib Versus Physician's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency

  NCT02975934· Phase 3· pharmaand GmbH· Source

• Completed

  Undiagnosed COPD and Asthma Population Study (UCAP)

  NCT03148210· Ottawa Hospital Research Institute· Source

• Completed

  Study of Pembrolizumab (MK-3475) or Placebo With Chemoradiation in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-412/KEYNOTE-412)

  NCT03040999· Phase 3· Merck Sharp & Dohme LLC· Source

• Completed

  Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-522/KEYNOTE-522)

  NCT03036488· Phase 3· Merck Sharp & Dohme LLC· Source

Conditions

Diseases this institution publishes on or runs trials for.

• Bipolar disorder21 works · 1 trial
• Charcot-Marie-Tooth disease3 works · 1 trial